Meta-analysis Of The Association Between Sclerostin And Vascular Calcification,Cardiovascular Events And Mortality In Patients With CKD

Aim:Through systematic review and meta-analysis,we aim to investigate the effects of sclerostin(SOST)on vascular calcification(VC),cardiovascular event(CVE),cardiovascular mortality and all-cause mortality in patients with chronic kidney disease(CKD).The main outcome was the relationship between SOST and VC,CVE,cardiovascular mortality and all-cause mortality.Method:Data was searched by the computer,Pubmed,Embase,Cochrane,Web of Science,China knowledge Network,Wanfang database and VIP database were used to search the research published up to June 2020.The risk ratio(HR)or odds ratio(OR),extracted from the included study was analyzed by Stata after logarithmic conversion of HR value and OR value.Result:We included a total of 17 prospective observational studies involving 3533 patients(a minimum of 91 and a maximum of 673).In the final analysis,three studies showed that there was no significant correlation between SOST and VC(HR=0.90,95%CI 0.28-2.90,I~2=97.6%,p=0.000).Five studies showed that there was no significant correlation between the level of SOST and the risk of CVE(HR=1.47,95%CI 0.43-3.44,I~2=86.2%,p=0.000).Three studies showed that there was no significant correlation between SOST and the risk of cardiovascular death(HR=1.17,95%CI 0.53-2.55,I~2=78.3%,p=0.010).Seven studies showed that there was no significant correlation between SOST levels and the risk of all-cause death(HR=0.93,95%CI 0.58-1.51,I~2=82.6%,p=0.000),Meta regression showed that the difference in SOST concentration between studies was an important source of heterogeneity.Conclusion:Although most of these studies are highly heterogeneous and the results are contradictory,our combined results show that serum SOST in patients with CKD are not related to VC,CVE,and all-cause/cardiovascular mortality.